MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

Phase 2CompletedNCT00266344

H. Lundbeck A/S520 enrolled

Overview

A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

520

Conditions

Primary Insomnia

Interventions

MK0928, gaboxadol / Duration of Treatment 3 WeeksDRUG

Placebo / Duration of Treatment 3 WeeksDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a diagnosis of primary insomnia Exclusion Criteria: * Patients with an active psychiatric disorder other than primary insomnia

Outcomes

Primary Outcomes

Patient-reported total sleep time.

Secondary Outcomes

Patient-reported time to sleep onset, number of awakenings, wake time after sleep onset and premature awakening.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.